Drawing for ADVANCING CANCER CARE IN AMERICA

USPTO serial 76390378

ADVANCING CANCER CARE IN AMERICA

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
BAIRD, MICHAEL
Law office
TTAB

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 604: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with ADVANCING CANCER CARE IN AMERICA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Richard D. Fladung

RICHARD D FLADUNG AKIN GUMP STRAUSS HAUER & FELD LLP44TH FL 1111 LOUISIANA STHOUSTON, TX 77002UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
016Printed materials, namely, brochures, web pages, and notices related to cancer and related public health issuesABANDONEDApr 29, 2002

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 28, 2005MAB4ABANDONMENT NOTICE MAILED - INTER PARTES DECISION—
Jun 28, 2005ABN4ABANDONMENT - AFTER INTER PARTES DECISION—
Jun 28, 2005OP.TOPPOSITION TERMINATED NO. 999999—
Jun 28, 2005OP.SOPPOSITION SUSTAINED NO. 999999—
Feb 12, 2005OP.IOPPOSITION INSTITUTED NO. 999999—
Nov 12, 2004ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Oct 12, 2004PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 22, 2004NPUBNOTICE OF PUBLICATION—
Aug 17, 2004PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 16, 2004ALIEASSIGNED TO LIE—
Aug 11, 2004CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 6, 2004TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 25, 2004TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 22, 2004CFITCASE FILE IN TICRS—
Sep 12, 2003TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 12, 2003CNRUDISAPPROVAL - AMENDMENT TO USE MAILED—
Mar 11, 2003AAUDAMENDMENT OF ALLEGED USE DISAPPROVED—
Mar 10, 2003AUPCAMENDMENT TO USE PROCESSING COMPLETE—
Feb 20, 2003CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 20, 2003MAILPAPER RECEIVED—
Feb 20, 2003MAILPAPER RECEIVED—
Feb 14, 2003CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 14, 2003IUAFUSE AMENDMENT FILED—
Aug 15, 2002CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 8, 2002DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance